'김갑성' 기자의 전체기사
-
Medit Announces 2025 Year-End Promotion
SEOUL, South Korea, Dec. 15, 2025 -- Medit, a global leader in 3D dental scanning solutions, announced the launch of "Medit's 2025 End of Year Promotion," a limited-time campaign delivering significant benefits to dental professionals worldwide. Dental professionals can learn more about the promotion details and encourage to leave their contact information at https://www.medit.com/medit-mobility-trade-up-promotion2025/. The promotion celebrates the debut of the Medit i900 Mobility, offering exclusive launch promotions alongside major upgrade opportunities across the Medit i9
- 김갑성 기자
- 2025-12-15 16:00
-
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
[ 메디채널 김갑성 기자 ] Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 years Of the 286 adult patients dosed in the trial, 69 have already completed the full 2-year treatment period and of those, 65 entered voluntarily into the Open Label Extension (OLE) study, representing 94% OLE uptake The study has now successfully passed seven sc
- 김갑성 기자
- 2025-12-15 15:02
-
Viva Biotech's invested and incubated company, Arthrosi, h…
STOCKHOLM, Dec. 15, 2025 -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026. Viva Biotech expects that the
- 김갑성 기자
- 2025-12-15 14:06
-
Everest Medicines Announces 2030 Strategy and Increase…
SHANGHAI, Dec. 15, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, outlining a comprehensive five-year roadmap to drive sustainable growth. Under this strategy, the Company aims to further deepen its product pipeline, maximize the value of its commercial platform, and advance the globalization of its research and development ("R&D") and commercializa
- 김갑성 기자
- 2025-12-15 12:40
-
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Compani…
SINGAPORE, Dec. 15, 2025 -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines. This honor builds on AbbVie's inclusion in the 2025 Best Workplaces in Asia™ list earlier this year – recognition that spans a wide geographic area assessed by Great Place to Work, covering markets across Asia and the Middle East. It underscores the strength, consistency and quality of our employee experienc
- 김갑성 기자
- 2025-12-15 09:00
-
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo. Primary evaluation period expected to complete in March 2026, with results in June 2026. CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition. MELBOURNE, Australia, Dec. 15, 2025 -- Cynata Therap
- 김갑성 기자
- 2025-12-15 08:25
-
ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital De…
SEOUL, South Korea, Dec. 13, 2025 -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant guide and prosthetic production processes on the platform and includes clinical case-based testing as well as coordination with local production partners. ALL CONEC operates a digital dental platform that integrates workflows for lab requests, design, production, settlement, and record tracking. The
- 김갑성 기자
- 2025-12-13 08:00
-
Keeping Loved Ones Active and Healthy During the Holidays…
NEW YORK, Dec. 12, 2025 -- The holiday season is a time for family, celebration, and cherished moments. For individuals who rely on respiratory support, maintaining energy and wellness can be a challenge amid busy schedules, colder weather, and seasonal changes. VARON highlights practical solutions to help families ensure their loved ones stay active, healthy, and engaged throughout the festive season. Supporting Respiratory Health Through the Holidays For many seniors and individuals with chronic respiratory conditions, having access to reliable oxygen the
- 김갑성 기자
- 2025-12-12 23:16
-
Strategic Partnership | Sanyou Bio and KanryBio Forge Partne…
SHANGHAI, Dec. 12, 2025 -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio") announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and products for biomarker assay kits. By integrating Sanyou Bio's core strengths in innovative biologics discovery with KanryBio's expertise in kit product development and manufacturing, the collaboration aims to provide global biopharmaceutical R&D clients with more efficient, precise, and rel
- 김갑성 기자
- 2025-12-12 22:00
-
United Imaging Intelligence at RSNA 2025: Reshaping Medicin…
SHANGHAI, Dec. 12, 2025 -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group, framed that vision with a timely question: "Agent Radiologist: Are We There Yet?" The company invited attendees to experience a new generation of AI agents capable of understanding, reasoning, and acting across the entire care pathway, bringing more precise and acce
- 김갑성 기자
- 2025-12-12 22:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
- SKF completes previously announced divestment of non-core aerospace operation in Elgin, USA 03:36
- DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion 03:34
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 31일 17시 40분